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Abstract
Objectives—Pediatric colonic eosinophilia represents a confounding finding with a wide 
differential. It is often difficult to determine which children may progress to inflammatory bowel 
disease (IBD), which have an eosinophilic colitis (EC), and which may have no underlying 
pathology. There is little guidance for the practitioner on the approach to these patients. To define 
the clinical presentations of colonic eosinophilia and identify factors which may aid in diagnosis 
we reviewed patients with colonic eosinophilia and the clinicopathologic factors associated with 
their diagnoses.
Methods—An 8-year retrospective chart review of children whose histopathology identified 
colonic eosinophilia (N=72) compared to controls with normal biopsies (N=35).
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Results—Patients with colonic eosinophilia had increased eosinophils/high power field (eos/
HPF) compared to controls (p<0.001) and had three clinical phenotypes. Thirty six percent had an 
inflammatory phenotype with elevated ESR (p < .0001), chronic inflammation on colonic biopsies 
(p<0.001) and were diagnosed with IBD. Thirty seven percent were diagnosed with EC, associated 
with male gender (p <0.005) and peripheral eosinophilia (p=0.041). Twenty one percent had no 
significant colonic pathology. Forty three percent of patients had more than one colonoscopy and 
68% of these had change from initial diagnoses.
Conclusions—There are three main phenotypes of children with colonic eosinophilia. Signs of 
chronic systemic inflammation raise suspicion for IBD. Peripheral eosinophilia and male gender 
are associated with EC. A significant percent of children with colonic eosinophilia do not have 
colonic disease. Eos/HPF is not reliable to differentiate etiologies. Repeat colonoscopies may be 
required to reach final diagnoses.
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Introduction
Colonic eosinophilia represents a challenging histological feature observed in some pediatric 
patients undergoing evaluation for common gastrointestinal complaints. Pathological 
guidelines distinguishing normal from abnormal numbers of colonic eosinophilia are scarce 
and have found variable results with mean maximum eosinophils/high powered field (eos/
HPF) in the cecum from 14 to 471–4 in normal children, and geographic variation has been 
described as well5. Little is known about the prognosis or pathogenesis of this finding in the 
absence of some clear causes such as parasitic infection, drug reaction, bone marrow 
transplant, collagen vascular disease, radiation treatment, or constipation6.
Children and adolescents with colonic eosinophilia often do not respond to dietary 
restriction7 suggesting that food allergy is not the primary driver of colonic eosinophilia in 
these patients. However, in infants colonic eosinophilia appears to have a defined allergic 
reaction8, 9. Clinical experiences suggest that colonic eosinophilia may be a subset of 
inflammatory bowel disease (IBD)10–13. Other studies describe colonic eosinophilia as 
preceding11 or overlapping14 the diagnosis of IBD, yet this has not been well defined15. 
Another group of patients with colonic eosinophilia, without evidence of IBD or other 
known cause, has been described and termed eosinophilic colitis (EC). Adult series suggest 
EC can be either a self-limited condition or have a waxing and waning course16. Significant 
difficulties arise in differentiating EC from IBD as they can present with similar symptoms. 
Previous studies have not delineated clinicopathologic factors which may help the clinician 
to distinguish between this diverse group of diseases. To better understand the clinical 
ramifications of colonic eosinophilia, we performed a retrospective analysis of children seen 
at a single institution who had an initial pathological report of “colonic eosinophilia”. The 
aims of our study were; 1) to compare control colon biopsies to patients with colonic 
eosinophilia to better define colonic eosinophilia, 2) to delineate clinicopathologic factors 
which may help identify patients with IBD vs. EC vs. other diagnoses, 3) to determine if 
repeat colonoscopy clarified the diagnoses.
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Materials and Methods
Subject selection
A search of the Children’s Hospital Colorado Department of Pathology database from 2006–
2013 was conducted using the search terms “Colonic eosinophilia”, “Eosinophilic colitis” 
“Eosinophilia” or “Increased Eosinophils”. Because there is no agreed upon definition for 
normal vs. abnormal numbers of eosinophils in the pediatric colon, we did not use a specific 
number cutoff of eosinophils to select subjects but instead reviewed all records in which 
pathologist’s interpretation was stated to be one of these above terms. We identified this 
cohort as having “colonic eosinophilia”.
A similar search of the Children’s Hospital Colorado Department of Pathology database was 
conducted to identify controls. These control subjects were previously identified at our 
institution17, had common symptoms of gastrointestinal dysfunction (abdominal pain, 
diarrhea, concern for juvenile polyp). They underwent upper endoscopy and colonoscopy 
without endoscopic or histologic pathology (except juvenile polyp), without mention of 
increased eosinophils or any features of acute or chronic inflammation. There was no 
evidence of elevated inflammatory markers (ESR, CRP), anemia or history of any use of 
medications likely to alter eosinophil numbers in the colon (systemic steroids, 5-
aminosalicylates, immunomodulators, biologic therapies, or antibiotics). We termed this 
cohort “controls”.
Electronic medical records review (EMRs) identified clinical features of control subjects and 
those with colonic eosinophilia, which included demographics, symptoms, laboratory 
testing, endoscopic findings and final diagnoses.
Ulcerative colitis (UC), Crohn’s disease (CD), and indeterminate colitis were combined for a 
diagnosis of “Any IBD” and separated into discrete categories. Laboratory studies 
performed within 1 month of colonoscopy were included in analysis.
Exclusion criteria included: 1. Under 1 year of age at initial biopsy-diagnoses of allergic 
colitis, 2. Bone marrow transplant or 3. Parasitic infection. This study was approved by the 
Institutional Review Board at the University of Colorado.
Specimen Histological Assessments
All hematoxylin and eosin (H&E) stained colonic tissue sections from “colonic 
eosinophilia” subjects were assessed by a board certified pediatric pathologist (KC). Signs 
of chronic inflammation on histopathology were identified by the pathologist (KC) when 
distorted gland architecture, multiple branched glands, Paneth cells in the left colon and/or 
fibrosis were present. Entire specimens were reviewed and the area with highest eosinophil 
density was selected to enumerate peak number of eosinophils/high powered field (eos/HPF) 
at ×40 magnification field size of 0.26 mm2.
Colonic biopsies from control subjects were evaluated in a similar fashion by the pathologist 
(KC) as well as 4 independent observers (ED, JM, JM, SF). Using 92 pathological slides 
from 35 controls, inter-observer reliability between these observers and KC was evaluated 
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by pair-wise Bland-Altman plot analysis. Intra-class correlation coefficient was greater than 
0.85 suggesting strong agreement.
Statistical analysis
SAS 9.4 (SAS Institute Inc., Cary, NC, USAS) was used for all the analyses. Associations of 
max eos/HPF with other continuous variables were assessed using spearman correlation. 
Two independent sample t-test and Chi square test were used respectively to compare 
continuous and categorical outcomes between controls and patients with eosinophilia and 
between patients with and those without IBD diagnosis. A linear mixed effects model with 
unstructured covariance was used to compare max eos across three segments of colon and 
between patients with and without IBD. P value less than 0.05 was deemed to be significant.
Results
Patient demographics and history
Review of our pathology database identified 78 patients with colonic eosinophilia. Six were 
not included based on exclusion criteria. Comparison of colonic eosinophilia patients to 
controls revealed that they were younger at the first colonoscopy, more often reported a 
history of environmental allergies, eczema, asthma and a family history of allergic and/or 
gastrointestinal disease (Table 1).
Evaluation of eos per HPF in the colon
We next assessed the peak mucosal eosinophils in those with colonic eosinophilia and 
normal controls at each section of the colon and compared the means of peak counts of 
different groups (Figure 1). Patients with colonic eosinophilia had significantly greater mean 
numbers of eos/HPF in the cecum/ascending colon (colonic eosinophilia 56.0 +/− 20.5, 
control 24.2 +/− 10.2,) transverse/descending (colonic eosinophilia 46.7 +/− 23.1, control 
18.8 +/− 8.1) and recto sigmoid colon (colonic eosinophilia 43.2 +/− 24.6, control 11.7 +/
− 7.1) p< 0.001 for differences in means for all locations.
Diagnosis and presentation of Colonic Eosinophilia
Patients with colonic eosinophilia presented with a variety of symptoms. The three most 
common of which included abdominal pain (59%), hematochezia (47%) and diarrhea (39%) 
(Figure 2A). Patients with known or suspected eosinophilic esophagitis (EoE) underwent 
colonoscopy for symptoms raising suspicion for colonic dysfunction (lower abdominal pain, 
hematochezia, diarrhea). A final diagnosis of eosinophilic gastrointestinal disease (EGID or 
EC) (EC, with or without enteritis, or gastritis) was seen in 27/72 patients. IBD (CD (N=10), 
UC (N=6) or IC (N=10)) was found in 26/72 (36%) patients. A combination of other 
diagnoses (other) such as toddler’s diarrhea, constipation, collagenous colitis, lymphocytic 
colitis, irritable bowel syndrome (IBS), no colonic pathology, eosinophilic esophagitis (EoE) 
and unknown/lost to follow up were identified in 35/72 (49%). (Figure 2B). Median follow 
up was 12 months, range 0–84 months. Some patients had multiple diagnoses which were 
not mutually exclusive. We next focused our assessment to understand differences between 
patients presenting with colonic eosinophilia who ultimately received diagnoses of IBD, EC, 
or other diagnoses.
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Evaluation of Colonic Eosinophilia in IBD vs. other diagnoses
As a primary differentiating step, we compared colonic eosinophilia between patients with 
IBD and patients without IBD. We found that mean maximum eos/HPF were not 
significantly different between the two groups in the cecum/ascending colon (62.5 +/− 20.3 
vs. 52.4 +/− 20.0 p= 0.078) or transverse/descending colon (53.9 +/− 27.0 vs. 42.6 +/
− 19.75, p= 0.065), but were in the rectosigmoid colon (56.6 +/− 28.1 vs. 37.5 +/− 20.9 p= 
0.0081). However, there was significant overlap between the two groups in all locations 
(Figure 3).
We next evaluated clinicopathologic factors in patients with final diagnoses of IBD vs. other 
diagnoses (Table 2). Significant differences between groups included: age at biopsy (p= 
0.0003), hemoglobin level (p= 0.0217), with corresponding difference in hematocrit, 
erythrocyte sedimentation rate (p < 0.0001), percent of patients who presented with: 
hematochezia (p= 0.0002), vomiting (p= 0.0065), and signs of chronic colitis on initial 
biopsy (p < 0.001). Signs of chronic colitis on biopsy was the most sensitive marker for IBD 
with only 4 patients who did not have chronic changes on initial colonic biopsy who were 
diagnosed with IBD. 3 of these patients were diagnosed with Crohn’s disease because of 
findings in the small bowel consistent with Crohn’s disease. We found that 41% of patients 
not diagnosed with IBD had a concurrent diagnosis of EoE whereas no patients with IBD 
met criteria for EoE (p= 0.0001). No significant differences were found in gender, white 
blood cell count (WBC), peripheral blood eosinophil count, C-reactive protein (CRP), serum 
albumin, or presenting symptoms of diarrhea, abdominal pain, weight loss/poor weight gain, 
or location of eosinophils (confined to the lamina propria compared to infiltrating the 
epithelium and/or crypts). Finally (Table S1), we evaluated the relationship of number of 
eos/HPF to the same variables as in Table 2 and determined that patients with hematochezia 
and vomiting had significantly different numbers of eosinophils in the colon.
Comparison of patients without IBD, EC/EGID vs. all other diagnoses
As a secondary differentiating step, patients with colonic eosinophilia without IBD were 
further evaluated to attempt to define their diagnoses (Table 3). Significant differences 
between groups (N=27 for EGID/EC and N=19 for non-IBD, non-EGID) included male 
gender (77.8 vs. 36.8% p = 0.005), and mean peripheral blood eosinophil count (820 vs. 323 
cells/μL p = 0.041). No other significant differences were found in clinical, lab, or histologic 
factors assessed. Of the 19 patients with colonic eosinophilia without diagnosis of IBD or 
EC, 15 of 19 eventually were determined to not have colonic pathology. Seven were 
ultimately diagnosed with EoE based on symptoms of esophageal dysfunction and histologic 
findings of > 15 eosinophils per HPF in esophageal biopsies after proton pump inhibitor 
trials, and no colonic pathology based on resolution of eosinophilia on repeat colonoscopy 
and/or resolution of any lower GI symptoms at the end of follow up period. Five were 
diagnosed with functional GI disorders, 2 with constipation, 1 with toddler diarrhea which 
resolved with time. Two of 19 were diagnosed with rarer types of colitis (1 lymphocytic and 
1 collagenous colitis), and 2 were lost to follow up (Table 4). This analysis showed that 15 
(21%) of the initial 72 patients with colonic eosinophilia did not have significant colonic 
pathology after clinical and endoscopic follow up.
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Repeat colonoscopy for colonic eosinophilia
We determined that 31/72 (43.1%)of the patients with colonic eosinophilia found on the 
initial colonoscopy had diagnoses that remained uncertain and/or continued to have clinical 
symptoms, and underwent a second colonoscopy (Figure 4A). Sixty eight percent of patients 
who received 2 or more colonoscopies had a change in diagnosis (Figure 4B). Patients 
underwent the second colonoscopy on average 1.14 +/− 0.96 years after the first 
colonoscopy. Analysis of this subgroup revealed that, after the first colonoscopy, 11 patients 
had an undefined diagnosis, 10 patients had diagnosis of IBD and 7 had an original 
diagnosis of EGID/EC. After repeat colonoscopies, these numbers changed to 0 undefined, 
14 with IBD and 10 with EGID/EC, and 4 patients without signs or symptoms of colonic 
pathology (Figure 4C).
Discussion
The aim of our study was to aid clinicians in understanding pediatric colonic eosinophilia. A 
major question in pediatrics is: how to define pathologic colonic eosinophilia, and can the 
number of eos/HPF delineate etiology? We found a significant difference in the mean of the 
peak eos/HPF in all locations in the colon between patients with colonic eosinophilia and 
controls. However, one novel aspect of our study is the significant variability found in 
controls and in children with colonic eosinophilia and the overlap of peak eos/HPF between 
control patients and those thought to have colonic eosinophilia. This variability likely 
contributes to the lack of consensus of normal versus abnormal eos/HPF. Different published 
studies have found different numbers of eos/HPF in healthy children as well as a decrease in 
eos/HPF as one moves distally along the colon1–3, 18, 19, which we have confirmed. As there 
is no consensus for pathologic colonic eosinophilia versus normal variation, we did not rely 
on a number cutoff to identify patients but rather pathologist interpretation of the biopsies as 
this is the situation frequently encountered by clinicians based on current knowledge. We 
were unable to define a clinically useful number cutoff for normal and abnormal eos/HPF 
given the significant overlap between our normal controls and patients with colonic 
eosinophilia. Any number chosen based on our sample would either misidentify many 
normal patients as abnormal or fail to identify many patients with pathologic colonic 
eosinophilia.
At first glance our study appears to have different results for the control biopsies compared 
to a recent cohort of healthy Canadian children4. Our numbers of mean peak eos/HPF of 
24.2, 18.8, and 11.7 for the cecum/ascending, transverse/descending, and rectosigmoid colon 
respectively are approximately half those found in the Canadian study, however the HPF 
area for their study was 0.55 mm2 and our HPF area was roughly half at 0.26 mm2. Our 
study has similar results to DeBrosse et al 20062 in the control subjects with their peak 
means 20.3, 16.3, and 8.3 for the ascending, transverse colon, and rectum respectively. Their 
HPF area was 0.28 mm2. The slight difference in means is likely accounted for by the 
variation in healthy patients and slightly different biopsy locations between studies. This 
highlights two difficulties in interpreting eos/HPF between published studies. The biopsy 
sites may be different, and there is no standardization for the area of HPFs. This places the 
responsibility on the clinician to confirm HPF area at their institution before interpreting 
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eos/HPF results in relation to published studies, unless HPF areas can be standardized in the 
future. Overall our analysis of control patients compared with those with colonic 
eosinophilia leads to the conclusion that eosinophils should be enumerated on biopsy reports 
to help guide the practitioner, but that the number of eos/HPF is not sufficient for diagnosis 
and other clinical factors must be considered.
We found 3 main groups of patients with colonic eosinophilia, which are important to 
distinguish: IBD, EC, and no significant colonic pathology. For the clinician, a major 
question that will guide future management for a patient with colonic eosinophilia is if the 
child has IBD. IBD was diagnosed in 36% of patients in our sample, which is similar to 
what has been described previously19. The IBD group is characterized by an older age at 
presentation (mean 11.88 years versus 7.25) a significant inflammatory picture with elevated 
ESR, chronic inflammatory changes on colonic biopsy and hematochezia. No single factor 
reliably predicted diagnosis of IBD, but the whole patient presentation was considered. Even 
chronic changes on initial biopsy was not specific as 21.7% of patients without IBD had 
chronic changes on initial biopsy. Of these, 8 patients were diagnosed with EC as their 
biopsies were not classic for IBD given the eosinophilic predominance of their 
inflammation, 1 was diagnosed with collagenous colitis, and 1 had resolution of both 
chronic changes and colonic eosinophilia on repeat colonoscopies. We found that eos/HPF, 
CRP, albumin, and weight loss were not reliable ways to identify patients with IBD. 
Unfortunately, too few of the patients we evaluated had fecal calprotectin testing performed 
making it impossible to analyze this as a diagnostic test to assist in the differentiation of IBD 
and other causes of colonic eosinophilia. Interestingly, patients with IBD were less likely to 
present with vomiting. This is likely related to 41% of patients in the non-IBD group also 
were diagnosed with EoE compared to none of the patients with IBD. This could help the 
clinician, in that, if a patient has colonic eosinophilia and meets criteria for EoE, it is 
unlikely that IBD is the underlying etiology, and primary EC or another etiology should be 
considered.
If a patient with colonic eosinophilia does not fit the clinical picture for IBD, the next 
important populations to distinguish are EC from other etiologies. We found that the factors 
associated with EC included higher peripheral eosinophil counts and male gender. These 
associations have previously been described in patients with eosinophilic gastrointestinal 
diseases20–22 and warrant additional studies. Twenty one percent of patients identified with 
colonic eosinophilia did not have significant colonic pathology based on resolution of lower 
GI symptoms or normal histology on repeat colonoscopies. Again, this highlights that the 
number of eos/HPF alone is not a reliable indicator for underlying etiology and the whole 
clinicopathologic picture must be considered. Since a significant proportion of patients with 
colonic eosinophilia may not have significant underlying colonic disease, the diagnostic and 
treatment approach must be tailored to the individual patient. Another consideration is that 
IBD may have years of quiescence between flares. It is possible that some patients who were 
identified as colonic eosinophilia with subsequent symptomatic resolution may go on to 
develop more classic signs and histology of IBD in the future, but this would need to be 
evaluated in further long term studies.
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There were many patients for whom the diagnosis after initial colonoscopy was unclear or 
who had continued symptoms. This prompted 43% to undergo at least one additional 
colonoscopy. In these patients, the diagnosis significantly changed (unclear to more clear 
diagnosis, change of initial diagnoses to alternate diagnoses) in 68% of patients, and the 
percent of patients with 2 or more diagnoses being considered decreased to 0. In children, 
the decision to repeat an invasive procedure is not taken lightly given concern over 
neurodevelopmental effects of repeat or prolonged anesthesia episodes23–25, potential for 
adverse events, and significant cost. However, we conclude from our study that in patients 
with colonic eosinophilia in whom the diagnosis is unclear or who are not improving, repeat 
colonoscopy is a reasonable step as in 2/3 of patients it can lead to a significant change in 
diagnosis and subsequent treatment.
Our study has several strengths: it is the largest population of pediatric patients with colonic 
eosinophilia to be studied, the only one to compare controls to colonic eosinophilia, evaluate 
clinicopathologic findings associated with colonic eosinophilia and examine the utility of 
repeat colonoscopy. Limitations to this study include that it was performed in a single 
referral center for eosinophilic gastrointestinal diseases and the study design was 
retrospective. In addition, we were unable to reliably determine use of medications at the 
time of colonoscopy. This study raises questions for future research including how to define 
pathologic colonic eosinophilia more reliably than eos/HPF. The lack of consensus on 
definition of pathologic colonic eosinophilia does not allow identification of a number cutoff 
of eos/HPF but rather the pathologist interpretation of increased eosinophils. We see from 
our population that choosing a number cutoff alone would not reliably differentiate normal 
from pathologic. Future research should move away from trying to define a normal number 
of eos/HPF and shift to focus on what other histologic factors may be a more reliable way to 
differentiate. Eotaxin staining, presence of eosinophil degranulation and IL-5 staining are 
some possibilities. Until more reliable factors are identified, there will continue to be 
significant difficulty in defining pathologic colonic eosinophilia.
Supplementary Material
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Acknowledgments
Support: NIH 1K24DK100303 (Furuta GT) and Consortium for Gastrointestinal Eosinophilic Researchers 
(CEGIR). CEGIR (U54 AI117804) is part of the Rare Diseases Clinical Research Network (RDCRN), an initiative 
of the Office of Rare Diseases Research (ORDR), NCATS, and is funded through collaboration between NIAID, 
NIDDK, and NCATS. (Furuta GT)
References
1. Saad AG. Normal quantity and distribution of mast cells and eosinophils in the pediatric colon. 
Pediatr Dev Pathol. 2011; 14:294–300. [PubMed: 21341989] 
2. DeBrosse CW, Case JW, Putnam PE, et al. Quantity and distribution of eosinophils in the 
gastrointestinal tract of children. Pediatr Dev Pathol. 2006; 9:210–8. [PubMed: 16944979] 
3. Lowichik A, Weinberg AG. A quantitative evaluation of mucosal eosinophils in the pediatric 
gastrointestinal tract. Mod Pathol. 1996; 9:110–4. [PubMed: 8657715] 
Mark et al. Page 8
J Pediatr Gastroenterol Nutr. Author manuscript; available in PMC 2019 May 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
4. Chernetsova E, Sullivan K, de Nanassy J, et al. Histologic analysis of eosinophils and mast cells of 
the gastrointestinal tract in healthy Canadian children. Hum Pathol. 2016; 54:55–63. [PubMed: 
27045513] 
5. Pascal RR, Gramlich TL, Parker KM, et al. Geographic variations in eosinophil concentration in 
normal colonic mucosa. Modern pathology : an official journal of the United States and Canadian 
Academy of Pathology, Inc. 1997; 10:363–365.
6. Alfadda AA, Storr MA, Shaffer EA. Eosinophilic colitis: epidemiology, clinical features, and 
current management. Therap Adv Gastroenterol. 2011; 4:301–9.
7. Katz AJ, Twarog FJ, Zeiger RS, et al. Milk-sensitive and eosinophilic gastroenteropathy: similar 
clinical features with contrasting mechanisms and clinical course. J Allergy Clin Immunol. 1984; 
74:72–8. [PubMed: 6547462] 
8. Bischoff SC. Food allergy and eosinophilic gastroenteritis and colitis. Curr Opin Allergy Clin 
Immunol. 2010; 10:238–45. [PubMed: 20431371] 
9. Bischoff SC, Ulmer FA. Eosinophils and allergic diseases of the gastrointestinal tract. Best Pract 
Res Clin Gastroenterol. 2008; 22:455–79. [PubMed: 18492566] 
10. Katsanos KH, Zinovieva E, Lambri E, et al. Eosinophilic-Crohn overlap colitis and review of the 
literature. J Crohns Colitis. 2011; 5:256–61. [PubMed: 21575892] 
11. Uzunismail H, Hatemi I, Dogusoy G, et al. Dense eosinophilic infiltration of the mucosa preceding 
ulcerative colitis and mimicking eosinophilic colitis: report of two cases. Turk J Gastroenterol. 
2006; 17:53–7. [PubMed: 16830279] 
12. Woodruff SA, Masterson JC, Fillon S, et al. Role of eosinophils in inflammatory bowel and 
gastrointestinal diseases. J Pediatr Gastroenterol Nutr. 2011; 52:650–61. [PubMed: 21593640] 
13. Bischoff SC, Wedemeyer J, Herrmann A, et al. Quantitative assessment of intestinal eosinophils 
and mast cells in inflammatory bowel disease. Histopathology. 1996; 28:1–13. [PubMed: 
8838115] 
14. Rothenberg ME. Eosinophilic gastrointestinal disorders (EGID). J Allergy Clin Immunol. 2004; 
113:11–28. quiz 29. [PubMed: 14713902] 
15. Choy MY, Walker-Smith JA, Williams CB, et al. Activated eosinophils in chronic inflammatory 
bowel disease. Lancet. 1990; 336:126–7.
16. Alfadda AA, Shaffer EA, Urbanski SJ, et al. Eosinophilic colitis is a sporadic self-limited disease 
of middle-aged people: a population-based study. Colorectal Dis. 2014; 16:123–9. [PubMed: 
24138295] 
17. Masterson JC, Capocelli KE, Hosford L, et al. Eosinophils and IL-33 Perpetuate Chronic 
Inflammation and Fibrosis in a Pediatric Population with Stricturing Crohn’s Ileitis. Inflammatory 
Bowel Diseases. 2015; 21:2429–2440. [PubMed: 26218140] 
18. Gonsalves N. Food allergies and eosinophilic gastrointestinal illness. Gastroenterol Clin North Am. 
2007; 36:75–91. vi. [PubMed: 17472876] 
19. Pensabene L, Brundler M-A, Bank JM, et al. Evaluation of Mucosal Eosinophils in the Pediatric 
Colon. Digestive Diseases and Sciences. 2005; 50:221–229. [PubMed: 15745076] 
20. Liacouras CA, Furuta GT, Hirano I, et al. Eosinophilic esophagitis: updated consensus 
recommendations for children and adults. J Allergy Clin Immunol. 2011; 128:3–20. e6. quiz 21–2. 
[PubMed: 21477849] 
21. Orenstein SR, Shalaby TM, Di Lorenzo C, et al. The spectrum of pediatric eosinophilic esophagitis 
beyond infancy: a clinical series of 30 children. Am J Gastroenterol. 2000; 95:1422–30. [PubMed: 
10894574] 
22. Jacobson LB. Diffuse eosinophilic gastroenteritis: an adult form of allergic gastroenteropathy. 
Report of a case with probable protein-losing enteropathy. Am J Gastroenterol. 1970; 54:580–8. 
[PubMed: 5504216] 
23. Davidson AJ, Disma N, de Graaff JC, et al. Neurodevelopmental outcome at 2 years of age after 
general anaesthesia and awake-regional anaesthesia in infancy (GAS): an international multicentre, 
randomised controlled trial. The Lancet. 387:239–250.
24. Sun L. Early childhood general anaesthesia exposure and neurocognitive development. BJA: 
British Journal of Anaesthesia. 2010; 105:i61–i68. [PubMed: 21148656] 
Mark et al. Page 9
J Pediatr Gastroenterol Nutr. Author manuscript; available in PMC 2019 May 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
25. Wilder RT, Flick RP, Sprung J, et al. Early exposure to anesthesia and learning disabilities in a 
population-based birth cohort. The Journal of the American Society of Anesthesiologists. 2009; 
110:796–804.
Mark et al. Page 10
J Pediatr Gastroenterol Nutr. Author manuscript; available in PMC 2019 May 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
What is known
• Colonic eosinophilia in pediatrics is not well defined
• Peak number of Eosinophils is variable thus not diagnostic
• IBD has been associated with eosinophilia
What is new
• 3 phenotypes of Colonic Eosinophilia are identified
• Association of Age, sex and chronic disease with Colonic Eosinophilia
• Need for repeat colonoscopy to define diagnosis
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Figure 1. 
Black error bar identifies Mean peak eosinophils/HPF (eos/HPF) in control colonic (gray 
square) biopsies vs. patients with colonic eosinophilia (black circle). **** p<.0001
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Figure 2. A) Presenting symptoms of patients with colonic eosinophilia (percent). B) Final 
diagnoses of patients noted to have colonic eosinophilia (percent). Other includes
irritable bowel syndrome, EoE, lymphocytic colitis, constipation, toddler’s diarrhea (some 
patients received more than one final diagnosis such as EoE and EC).
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Figure 3. 
Peak eos/HPF by location in the colon in patients with colonic eosinophilia with diagnosis 
of inflammatory bowel disease (IBD) and without IBD (Non-IBD). Differences in peak 
mean eos/HPF were significantly different in the rectosigmoid (p = 0.008)
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Figure 4. 
A) Patient data for patients undergoing at least 2 colonoscopies B) Percent of patients with a 
clinically relevant change in diagnosis after repeat endoscopies. C) Diagnoses of patients 
after the first endoscopy and after 2 or greater endoscopies. Patients who had more than one 
possible diagnosis considered were labeled as Undecided. Several patients had multiple 
diagnoses that were not mutually exclusive and included in other.
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Table 1
General Patient Demographics and History comparing control biopsies to those with colonic eosinophilia
Controls (N=35) Colonic Eosinophilia (n=72) p-value
Female/Male (% Male) 20/15 (42.8) 30/42 (58) 0.13
Average age at 1st colonoscopy in years 11.37 (5.09) 8.92 (5.37) 0.0224
Average number colonoscopies 1 1.88
% with environmental/food or drug allergies 25.71 61.11 <0.001
% with asthma 2.86 34.72 <0.001
% with eczema 11.4 25.00 0.07
% with family history of GI illness 14.29 37.50 0.008
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Table 2
Selected clinicopathologic factors in patients with IBD vs. patients without IBD. Patients with IBD were 
significantly older, had higher ESR, lower hemoglobin, more likely to have chronic inflammation on colonic 
biopsy, were less likely to present with vomiting and less likely to have diagnosis of EoE. Number of patients 
(N), Standard deviation (SD)
IBD
N=26
Non IBD
N=46 P value
Age at Biopsy (yrs) [Mean (SD)] 11.88 (4.89) 7.24 (4.93) 0.0003
% male 53.8 60.9 0.56
Number of patients presenting with hematochezia [N (%)] 20 (76.9) 14 (31.1) 0.0002
Patients presenting with vomiting [N (%)] 1 (3.8) 14 (31.1) 0.0065
Patients presenting with diarrhea [N (%)] 7 (26.9) 21 (46.7) 0.1
Patients presenting with abdominal pain [N (%)] 16 (61.5) 26 (57.8) 0.76
Peak eosinophilia/HPF [Mean (SD)] 66.77 (24.60) 56.17 (22.17) 0.065
Eosinophils in the epithelium [N (%)] 14 (53.8) 19 (41.3) 0.304
Patients presenting with weight loss/poor weight gain [N (%)] 5 (19.2) 10 (22.2) 0.77
Patients with signs of chronic colitis on initial biopsy [N (%)] 22 (84.6) 10 (21.7) <0.001
Patients with the diagnosis of Eosinophilic esophagitis [N (%)] 0 (0) 19 (41.3) <0.0001
WBC [Mean (SD)] 9.00 (3.10) 8.54 (3.66) 0.64
Hgb [Mean (SD)] 12.33 (2.28) 13.65 (1.55) 0.022
Peripheral blood eosinophil count [Mean (SD)] 415.10 (434.56) 659.68 (848.24) 0.18
ESR [Mean (SD)] 22.43 (12.98) 6.75 (5.18) <.0001
CRP [Mean (SD)] 0.66 (0.75) 0.37 (0.55) 0.18
Albumin [Mean (SD)] 3.88 (0.55) 3.97 (0.58) 0.58
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Table 3
Selected clinicopathologic factors in patients with colonic eosinophilia diagnosed with eosinophilic colitis/
eosinophilic gastrointestinal disease (EC/EGID) vs. patients not diagnosed with either IBD or EC/EGID (non-
IBD, non-EC/EGID). Patients with EC/EGID were significantly more likely to be male and have elevated 
eosinophils in peripheral blood. Number of patients (N), standard deviation (SD).
Eosinophilic Colitis
N=27
Non-Eosinophilic colitis/Non-IBD
N=19 P value
Age at biopsy (yrs) [mean (SD)] 6.67 (4.83) 8.05 (5.08) 0.35
% male 77.78 35.8 0.005
Number of patients with signs of chronic colitis on initial biopsy [N 
(%)] 10 (29.63) 2 (10.53) 0.12
Number of patients presenting with hematochezia [N (%)] 9 (33.33) 5 (26.32) 0.61
Number of patients presenting with vomiting [N (%)] 9 (33.33 5 (26.32) 0.61
Number of patients presenting with diarrhea [N (%)] 13 (48.15) 8 (42.11) 0.69
Number of patients with abdominal pain [N (%)] 13 (48.15) 13 (68.42) 0.17
Number of patients with weight loss/poor weight gain [N (%)] 6 (22.22) 4 (21.05 0.93
Number of patients with the diagnosis of Eosinophilic esophagitis 
[N (%)] 12 (44.4) 7 (36.8) 0.6
WBC [Mean (SD)] 8.77 (3.99) 8.01 (2.96) 0.54
Hgb [Mean (SD)] 13.63 (1.73) 13.67 (1.18) 0.95
Peripheral blood eosinophil count [Mean SD)] 820 (979) 323 (279) 0.042
ESR [Mean (SD)] 6.45 (5.62) 7.5 (3.98) 0.86
CRP [Mean (SD)] 0.35 (0.44) 0.42 (0.83) 0.85
Albumin [Mean (SD)] 3.91 (0.69) 4.11 (0.27) 0.28
Peak eosinophilia/HPF [Mean (SD)] 54.74 (19.47) 58.21 (25.95) 0.63
Eosinophils in the epithelium [N (%)] 12 (44.4) 7 (36.8) 0.644
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Table 4
Diagnoses of patients with colonic eosinophilia without IBD or diagnosis of primary EC (n = 19). 7 patients 
had resolution of lower abdominal complaints and/or resolution of colonic eosinophilia on repeat endoscopy 
but met criteria for EoE (EoE). 5 patients had clinical course consistent with functional abdominal pain/IBS. 2 
patients had colonic eosinophilia but known histories of constipation and symptoms resolved with treatment of 
constipation. 1 patient had diarrhea as a toddler which resolved with time and no intervention. 2 patients had 
more rare colitites (collagenous and lymphocytic colitis). 2 patients were lost to follow up (family moved out 
of state) < 4 weeks after endoscopy without leading diagnosis.
Number of patients Final diagnosis
7 No colonic pathology, EoE
5 Functional/IBS
2 Constipation
1 Toddler diarrhea
1 Lymphocytic colitis
1 Collagenous colitis
2 Lost to follow up
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